A safety evaluation of raltegravir for the treatment of HIV.

about

Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

P2860

Q58760446-FDF10BA6-6E77-4A33-A365-0DCD198817A9

P2860

A safety evaluation of raltegravir for the treatment of HIV.

Item

http://www.wikidata.org/entity/Q47377203

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A safety evaluation of raltegravir for the treatment of HIV.

@en

A safety evaluation of raltegravir for the treatment of HIV.

@nl

type

Item

label

A safety evaluation of raltegravir for the treatment of HIV.

@en

A safety evaluation of raltegravir for the treatment of HIV.

@nl

prefLabel

A safety evaluation of raltegravir for the treatment of HIV.

@en

A safety evaluation of raltegravir for the treatment of HIV.

@nl

P1476

A safety evaluation of raltegravir for the treatment of HIV

@en

P2093

Jose R Arribas

http://www.w3.org/2001/XMLSchema#string

Rocio Montejano

http://www.w3.org/2001/XMLSchema#string

P2860

Retroviral intasome assembly and inhibition of DNA strand transfer

A historical sketch of the discovery and development of HIV-1 integrase inhibitors

Raltegravir with optimized background therapy for resistant HIV-1 infection

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

New first and second generation inhibitors of human immunodeficiency virus-1 integrase.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Integrase inhibitors to treat HIV/AIDS.

P304

217-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14740338.2018.1411903

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Natalia Stella-Ascariz

Rosa De Miguel

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29199485

http://www.w3.org/2001/XMLSchema#string

A safety evaluation of raltegravir for the treatment of HIV.

about

P2860

P2860

A safety evaluation of raltegravir for the treatment of HIV.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698